HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug ...

HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug ...

Detailed price information for Serina Therapeutics Inc (SER-A) from The Globe and Mail including charting and trades.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

-Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage ...

Serina Therapeutics is shedding a subsidiary to start the new year off debt-free. The Alabama-based biotech has sold UniverXome Bioengineering to antiaging company Juvenescence to clear away $11.2 ...

HUNTSVILLE, AL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform ™ drug ...

Serina Therapeutics has enrolled the first patient in its Phase Ib registrational trial of SER-252 for advanced Parkinson’s disease (PD). The study is assessing the safety, pharmacokinetics, ...

HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing drug candidates enabled ...

Serina Therapeutics, a clinical-stage biotechnology firm, has congratulated its strategic partner, Juvenescence Ltd., on successfully securing $150 million in Series B financing led by M42, a global ...

Serina Therapeutics secured a second $5 million funding tranche for advancing SER-252 into a Phase 1 trial in Parkinson's disease. Serina Therapeutics, Inc. has successfully closed the second $5 ...

- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded ...